Pages that link to "Q73253485"

The following pages link to Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS (Q73253485):

Displaying 41 items.

• The anti-Müllerian hormone type II receptor: insights into the binding domains recognized by a monoclonal antibody and the natural ligand (Q24306670) (← links)
• Animal models of ovarian cancer (Q24791470) (← links)
• Establishment, characterization and downstream application of primary ovarian cancer cells derived from solid tumors (Q28485444) (← links)
• Smad1-Smad5 ovarian conditional knockout mice develop a disease profile similar to the juvenile form of human granulosa cell tumors (Q30040477) (← links)
• Mullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivo (Q33897273) (← links)
• The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells (Q33911286) (← links)
• Müllerian inhibiting substance/anti-Müllerian hormone: A novel treatment for gynecologic tumors (Q34246272) (← links)
• Mullerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeutics (Q34279411) (← links)
• Mullerian Inhibiting Substance inhibits invasion and migration of epithelial cancer cell lines (Q34434627) (← links)
• Tissue-engineered cells producing complex recombinant proteins inhibit ovarian cancer in vivo (Q34713416) (← links)
• Mullerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107. (Q34789719) (← links)
• Anti-Müllerian hormone recruits BMPR-IA in immature granulosa cells (Q35060595) (← links)
• Identification of epithelial ovarian tumor-specific aptamers (Q35635298) (← links)
• Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer (Q35768666) (← links)
• Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance (Q35787316) (← links)
• AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer (Q35961381) (← links)
• The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer. Validation using the mAb 12G4. (Q36214988) (← links)
• Immuno-stimultory/regulatory gene expression patterns in advanced ovarian cancer (Q36248464) (← links)
• Regulation of Murine Ovarian Epithelial Carcinoma by Vaccination against the Cytoplasmic Domain of Anti-Müllerian Hormone Receptor II. (Q36296331) (← links)
• The Müllerian inhibiting substance type 2 receptor suppresses tumorigenesis in testes with sustained β-catenin signaling (Q36435768) (← links)
• Development of an efficiently cleaved, bioactive, highly pure FLAG-tagged recombinant human Mullerian Inhibiting Substance (Q36637142) (← links)
• Patterns of Müllerian Inhibiting Substance Type II and Candidate Type I Receptors in Epithelial Ovarian Cancer (Q36743937) (← links)
• Mullerian inhibiting substance suppresses proliferation and induces apoptosis and autophagy in endometriosis cells in vitro. (Q36989867) (← links)
• Serum anti-müllerian hormone levels in patients with epithelial ovarian cancer (Q37100987) (← links)
• Follicle Depletion Provides a Permissive Environment for Ovarian Carcinogenesis (Q37224153) (← links)
• The mammalian ovary from genesis to revelation (Q37385514) (← links)
• An albumin leader sequence coupled with a cleavage site modification enhances the yield of recombinant C-terminal Mullerian Inhibiting Substance (Q37693327) (← links)
• Müllerian inhibiting substance/anti-Müllerian hormone: a potential therapeutic agent for human ovarian and other cancers (Q37707380) (← links)
• Transcriptome analysis reveals that Müllerian inhibiting substance regulates signaling pathways that contribute to endometrial carcinogenesis. (Q38901206) (← links)
• Mullerian inhibiting substance induces apoptosis of human endometrial stromal cells in endometriosis. (Q39320089) (← links)
• Potential therapeutic applications of human anti-Müllerian hormone (AMH) analogues in reproductive medicine (Q39393122) (← links)
• Anti-Müllerian hormone inhibits growth of AMH type II receptor-positive human ovarian granulosa cell tumor cells by activating apoptosis (Q39496658) (← links)
• Identification of characteristic molecular signature of Müllerian inhibiting substance in human HPV-related cervical cancer cells (Q39542130) (← links)
• Expression of Müllerian inhibiting substance type II receptor and antiproliferative effects of MIS on human cervical cancer (Q39651067) (← links)
• Ovarian cancer stem cells: a new target for cancer therapy (Q42092160) (← links)
• Investigation of factors affecting the efficacy of 3C23K, a human monoclonal antibody targeting MISIIR. (Q47153253) (← links)
• Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts (Q47969294) (← links)
• The expression of Müllerian inhibiting substance/anti-Müllerian hormone type II receptor in myoma and adenomyosis. (Q48161883) (← links)
• Anti-Müllerian Hormone Expression in Endometrial Cancer Tissue (Q64087522) (← links)
• Anti-Müllerian Hormone in Fertility Preservation: Clinical and Therapeutic Applications. (Q64906343) (← links)
• Anti-Müllerian hormone inhibits proliferation and induces apoptosis in epithelial ovarian cancer cells by regulating the cell cycle and decreasing the secretion of stem cell factor. (Q64978891) (← links)